Welcome to our dedicated page for Pediatrix Medical Group news (Ticker: MD), a resource for investors and traders seeking the latest updates and insights on Pediatrix Medical Group stock.
Pediatrix Medical Group, Inc. provides specialized physician services in neonatal intensive care, maternal-fetal medicine, and pediatric subspecialties. This news hub offers investors and healthcare stakeholders centralized access to official announcements and material developments impacting this niche medical services provider.
Discover up-to-date press releases covering financial results, clinical quality initiatives, and hospital partnership expansions. Our curated collection includes updates on evidence-based care advancements, leadership changes, and operational milestones relevant to neonatal/pediatric healthcare delivery.
This resource serves investors requiring timely MD updates and medical professionals tracking care innovations. All content maintains factual accuracy without speculative commentary, aligning with regulatory standards for financial disclosures.
Bookmark this page for efficient tracking of Pediatrix Medical Group's strategic developments in high-risk obstetric and neonatal care markets. Verify critical updates through primary sources when making data-driven decisions.
Pediatrix Medical Group (NYSE: MD) announced its participation in two upcoming healthcare investor conferences. The company will present at the Leerink Partners Healthcare Crossroads Conference in Austin, TX, on May 30, 2024, at 9:20 am CT, followed by the Jefferies Global Healthcare Conference in New York, NY, on June 6, 2024, at 7:30 am ET. Both events are anticipated to provide insights into Pediatrix's business strategies and growth prospects. Investors can access audio webcasts of these presentations on Pediatrix's website.
Pediatrix Medical Group, Inc. reported earnings of $0.05 per share for the first quarter of 2024, with Adjusted EPS of $0.20. Net revenue was $495 million, net income was $4 million, and Adjusted EBITDA was $37 million. The company focused on operating efficiency and margin stabilization. Same-unit revenue increased by 2.3%, driven by patient volume growth. Expenses rose for clinical compensation and internal staffing. Adjusted EBITDA decreased to $37.2 million. Cash and cash equivalents were $8.0 million, with total debt of $705 million. The company expects 2024 Adjusted EBITDA to be $200-220 million.
FAQ
What is the current stock price of Pediatrix Medical Group (MD)?
What is the market cap of Pediatrix Medical Group (MD)?
